Jumpcode Genomics, a San Diego, CA-based genome technology company focused on improving the understanding of human disease, raised $21m in Series B funding.
The round, announced in January 2021, was co-led by Baird Capital and Arboretum Ventures with participation from existing investor LYZZ Capital. In conjunction with the funding, Frank Witney joined Jumpcode’s Board of Directors.
Founded in 2016 Led by Yaron Hakak, Ph.D., CEO, Jumpcode Genomics provides patented CRISPRclean technology which enables next-generation sequencing for researchers worldwide working in the fields of basic research, infectious disease, oncology and consumer genomics
The process fits within standard next-generation sequencing workflows and works with most commercially available library preparation solutions.
FinSMEs
19/02/2021